Skip to main content
FinSpry Logo
FinSpry
BIIB logo
BIIB
(NASDAQ)
Biogen Inc.
$200.62-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Biogen (BIIB) Stock Price & Financial Analysis

Biogen Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$196.92 - $203.60
52-Week High$219.72
52-Week Low$124.56
Open$197.04
Volume1.02M
Average Volume (3M)1.39M
Market Cap29.77B
Shares Outstanding148.40M
P/E Ratio (TTM)21.69
Forward P/E23.20
Price to Sales (P/S)3.00
Price to Book (P/B)1.60
EV/EBITDA12.59
Revenue (TTM)9.94B
Net Income (TTM)1.37B
Free Cash Flow (TTM)2.49B
EPS (TTM)$9.32
Profit Margin13.81%
Operating Margin17.35%
Return on Equity (ROE)7.36%
Debt to Equity0.34
50-Day MA$199.37
200-Day MA$181.70
52-Week Change53.17%
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%
Last Dividend Ex-DateFeb 2, 2017

Frequently Asked Questions About Biogen

What is the current stock price for BIIB?

As of the latest trading session, BIIB stock trades at $200.62. The 52-week range is $124.56–$219.72, with a day range of $196.91–$203.60.

What is the P/E ratio for BIIB?

Biogen's trailing P/E ratio is 21.7, meaning investors pay $21.7 for every $1 of annual earnings. The forward P/E is 23.2, reflecting analyst expectations for future earnings. Biogen operates in the Healthcare sector.

Does BIIB pay dividends?

Biogen does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for BIIB?

Based on 34 analysts, the consensus for BIIB is Buy.

What is the market cap of BIIB?

Biogen's market capitalization is $29.77B, classifying it as a large-cap company. Biogen operates in the Healthcare sector within the Drug Manufacturers - General industry.